S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Options Trading Plan–Perfect For Beginners (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
NASDAQ:AMRN

Amarin (AMRN) Stock Forecast, Price & News

$0.93
+0.02 (+2.21%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.89
$0.94
50-Day Range
$0.91
$1.43
52-Week Range
$0.89
$2.23
Volume
1.42 million shs
Average Volume
1.49 million shs
Market Capitalization
$373.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.81

Amarin MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
95.8% Upside
$1.81 Price Target
Short Interest
Healthy
4.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.16mentions of Amarin in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$312,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.22) to ($0.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

505th out of 963 stocks

Pharmaceutical Preparations Industry

232nd out of 458 stocks


AMRN stock logo

About Amarin (NASDAQ:AMRN) Stock

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN Price History

AMRN Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Amarin Reports Second Quarter 2023 Financial Results
Amarin appoints Patrick Holt CEO
Why Are Amarin Shares Plunging Today?
Amarin sinks 11% on plan to undergo restructuring
Amarin Corp Appoints Patrick Holt As President And CEO
See More Headlines
Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Company Calendar

Last Earnings
8/02/2023
Today
9/24/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
365
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$1.81
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+95.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-105,800,000.00
Pretax Margin
-12.44%

Debt

Sales & Book Value

Annual Sales
$369.19 million
Book Value
$1.47 per share

Miscellaneous

Free Float
368,252,000
Market Cap
$373.83 million
Optionable
Optionable
Beta
1.76

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Thomas Charles Reilly (Age 51)
    Chief Financial Officer
    Comp: $856.49k
  • Dr. Steven B. Ketchum Ph.D. (Age 58)
    Pres of R&D and Chief Scientific Officer
    Comp: $991.19k
  • Mr. Aaron D. Berg (Age 60)
    Exec. VP & Pres of U.S.
    Comp: $913.7k
  • Mr. Patrick Holt
    Pres, CEO & Director
  • Mr. Jordan Zwick (Age 36)
    Sr. VP of Corp. Bus. Devel. & Investor Relations
  • Ms. Donna Pasek
    Sr. VP of HR
  • Mr. Laurent Abuaf
    Pres of Europe & Sr. VP
  • Dr. Nabil Abadir
    Chief Medical Officer of Global Medical Affairs
  • Dr. David Keenan Ph.D.
    Exec. VP of Technical Operations & Pres of Europe













AMRN Stock - Frequently Asked Questions

Should I buy or sell Amarin stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View AMRN analyst ratings
or view top-rated stocks.

What is Amarin's stock price forecast for 2023?

3 equities research analysts have issued twelve-month price targets for Amarin's stock. Their AMRN share price forecasts range from $1.00 to $3.00. On average, they predict the company's share price to reach $1.81 in the next twelve months. This suggests a possible upside of 95.8% from the stock's current price.
View analysts price targets for AMRN
or view top-rated stocks among Wall Street analysts.

How have AMRN shares performed in 2023?

Amarin's stock was trading at $1.21 at the start of the year. Since then, AMRN stock has decreased by 23.5% and is now trading at $0.9257.
View the best growth stocks for 2023 here
.

Are investors shorting Amarin?

Amarin saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 16,500,000 shares, a drop of 9.5% from the August 15th total of 18,240,000 shares. Based on an average daily volume of 2,450,000 shares, the days-to-cover ratio is currently 6.7 days.
View Amarin's Short Interest
.

When is Amarin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our AMRN earnings forecast
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) issued its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). The biopharmaceutical company had revenue of $80.17 million for the quarter, compared to analyst estimates of $73.40 million. Amarin had a negative net margin of 11.06% and a negative trailing twelve-month return on equity of 6.56%.

What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ExodusPoint Capital Management LP (0.96%), Woodline Partners LP (0.56%), Price Jennifer C. (0.55%), Gratus Capital LLC (0.46%), Acadian Asset Management LLC (0.29%) and AlphaCentric Advisors LLC (0.14%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum.
View institutional ownership trends
.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $0.93.

How much money does Amarin make?

Amarin (NASDAQ:AMRN) has a market capitalization of $373.83 million and generates $369.19 million in revenue each year. The biopharmaceutical company earns $-105,800,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does Amarin have?

The company employs 365 workers across the globe.

Does Amarin have any subsidiaries?
The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More
How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com.

This page (NASDAQ:AMRN) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -